Gilead Sciences, Inc.

Daniel G Shore

Scott D Schroeder

James G Taylor

Michael Graupe

Lan Jiang

Stephen E Ammann

Jeromy J Cottell

Zheng-Yu Yang

Elbert Chin

Nathan E Wright

Gediminas J Brizgys

Chienhung Chou

Rhiannon Thomas-Tran

Chao-I Hung

Suzanne M Szewczyk

James S Cassidy

Kavoos Kolahdouzan

Scott E Lazerwith

Michael L Mitchell

Sheila M Zipfel

Eda Y Canales

Julian Andrew Codelli

Nathan D Shapiro

Yasamin Moazami

Weng K Chang

Henok H Kinfe

Christopher J Swank

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.

GLP-1R modulating compounds

The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.

Thienopyrrole compounds

Growing community of inventors

San Mateo, CA, United States of America

Daniel G Shore